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EFFECTS OF DIPYRIDAMOLE 
IN COMBINATION WITH 
ANTICOAGULANT THERAPY 
ON SURVIVAL AND 
THROMBOEMBOLIC EVENTS 
IN PATIENTS WITH 
PROSTHETIC HEART VALVES 
A meta-analysis of the 
randomized trials 
The addition of dipyridamole, an antiplatelet agent, to conventional 
anticoagulant regimens has been shown to reduce the frequency of embo- 
lization after valve replacement with a mechanical prosthesis. The purpose 
of this metalanalysis was to reevaluate the benefit of dipyridamole by 
analyzing the evidence from all randomized clinical trials. Summary data 
were extracted from the application to the Food and Drug Administration. 
Six randomized clinical trials had accrued 1141 patients, of whom 582 
received anticoagulant therapy alone and 559 received additional dipyrid- 
amole at dosages ranging from 225 to 400 mg per day. The events analyzed 
were all thromboembolic events, both fatal and nonfatal; hemorrhagic 
events, both fatal and nonfatal; and the overall mortality. The combination 
of dipyridamole with anticoagulants reduced the risk of thromboembolic 
events (fatal or nonfatal) by 56% when compared with the use of antico- 
agulants alone (p = 0.0001). The risk reduction was seen in fatal and in 
nonfatal thromboembolic events (risk reduction for fatal events, 64%, p = 
0.008; for nonfatal events, 50%, p = 0.005). The overall mortality rate was 
also significantly reduced by 40% in the group receiving dipyridamole (p= 
0.013). There was no difference between treatment groups with respect o 
hemorrhagic events (risk reduction, -1%, p = 0.94). This meta-analysis 
supports the use of dipyridamole in this setting and warrants further trials 
with new antiplatelet agents. (J THORAC CARDIOVASC SURG 1995;110:463-72) 
Hubert Pouleur, MD, a and Marc Buyse, ScD, b Brussels, Belgium 
E ven in the presence of adequate anticoagulant therapy with warfarin or similar compounds, 
serious thromboembolic events remain a frequent 
complication after valve replacement with a me- 
chanical prosthesis. >5 In 1971 Sullivan, Harken, and 
Gorlin 6 were the first to show that the addition of 
dipyridamole, an antiplatelet agent, to the conven- 
tional anticoagulant regimen significantly reduced 
the frequency of embolization. Other studies that 
pointed toward a similar conclusion followed 7-22 and 
dipyridamole ventually was granted approval for 
this indication in most countries. 
More recently, however, the clinical efficacy of 
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dipyridamole as an antiplatelet agent has been 
seriously questioned. 23 These criticisms, together 
with the publication of other trials that showed less 
convincing or equivocal results after valve replace- 
ment, 24'25 made it important to reconsider the 
possible benefits of the use of dipyridamole after 
mechanical valve replacement, in terms of both 
clinical efficacy and safety. With this purpose in 
mind, a meta-analysis of all available data obtained 
under controlled conditions was done. Meta-analy- 
sis, which consists of combining evidence from sev- 
eral sources, may be done in several ways not all of 
which are equally reliable. One approach, which is 
often regarded asthe gold standard of meta-analy- 
sis, consists of collecting individual patient data on 
all patients ever entered in randomized clinical 
trials. 26 At the other extreme, a commonly used 
approach consists of reviewing only published re- 
ports of clinical trials and extracting information 
from these publications. This approach has been 
criticized because it may be subject to publication 
bias and published reports typically do not contain 
the data needed for the meta-analysis. 27' 2s We have 
used yet another approach, because we were able to 
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Table I. Controlled trials using dipyridamole combined with anticoagulants (warfarin or similar compounds) 
in prevention of thromboembolic events in patients with prosthetic heart valves 
Follow-up Reported results or conclusions 
Treatments N End points (mo) as stated in the paper 
Sullivan i9716 AVK + placebo 84 Thromboembolic events: 12" Significant reduction of emboli- 
cerebral or peripheral zation in the dipyridamole 
and myocardial infarc- group 
tions when the embo- AVK + dipyridamole 79 No difference between death 
400 rag/day lus was proven by an rates 
autopsy 
Kasahara 19777 AVK alone 39 Any thromboembolic 27? Reduced incidence of thrombo- 
AVK + dipyridamole 39 event embolic events and deaths in 
400 rag/day dipyridamole group 
Boissel 1978 (PACTE) 24 AVK alone 202 Thromboembolic events 12' No trend in favor of the dipyri- 
including myocardial damole-treated group 
AVK + dipyridamole 183 infarctions and deaths 
375 rag/day of any cause 
Bran 19808 AVK alone 43 Thromboembolic events 
AVK + dipyridamole 58 and deaths 
up to 5 mg/kg per 
day 
Rajah 19809 AVK alone 87 Thromboembolic events 
AVK + dipyridamole 68 and deaths 
225 to 400 rag/day 
Starkman 198225 AVK alone 127 Thromboembolic events 
AVK + dipyridamolc 132 and deaths 
375 rag/day 
24* Dipyridamole r duces the inci- 
dence of thromboembolic 
events provided that daily 
dosage is adequate 
30:) Dipyridamole r duces ignifi- 
cantly the incidence of 
thromboembolic events 
12" Inconclusive r sults: a larger 
sample size would be neces- 
sary 
N, Number of patients; AVK, anticoagulants. 
*Fixed duration offollow-up for each patient. 
?Mean value, follow-up extended up to 45 months. 
:)Mean value, range i0 to 49 months. 
obtain access to the registration file that had been 
reviewed by the U.S. Food and Drug Administrat ion 
(FDA) to grant market authorization to dipyridam- 
ole. The registration file contains much more de- 
tailed information on the clinical trials than the 
corresponding publications, and therefore some of 
our analyses are based on data that have unti l  now 
remained unpublished. 
Methods 
Trial selection. All prospective, randomized, controlled 
trials that assessed the prevalence of thromboembolic 
events and deaths in a group treated with warfarin (or 
similar compound) plus dipyridamole and that compared 
this prevalence with that in a control group receiving the 
same anticoagulant therapy without dipyridamole were 
considered eligible for inclusion in this meta-analysis. 
Noncontrolled studies and retrospective studies 1°-22 
were not included. The trials were identified by a system- 
atic search through the MEDLINE database and from the 
documentation submitted to the FDA for approval of the 
use of dipyridamole in the prevention of thromboembolic 
events in patients with prosthetic heart valves. Six trials 
that met the eligibility criteria were found (Table I). They 
included a total of 1141 patients, of whom 582 received 
anticoagulant therapy alone and 559 received in addition 
dipyridamole at dosages ranging from 225 to 400 mg per 
day. The duration of follow-up is listed in Table I. In all 
but one trial (the PACTE trial 24) the patients were 
randomized after operation. Details on the anticoagulant 
treatment used in each trial are provided in Table II. 
Data extraction. The events analyzed were all throm- 
boembolic events, both fatal and nonfatal; hemorrhagic 
events, both fatal and nonfatal; and the overall mortality. 
Thromboembolic events included all cerebral emboli, 
other arterial emboli, and myocardial infarctions and 
strokes. Only two deaths were classified as sudden; these 
sudden deaths were also considered as thromboembolic 
events to avoid any bias in the assessment of such events. 29 
Summary data were extracted from the published papers 
and from the documentation submitted to the FDA by two 
independent observers and then compared for possible 
discrepancies to reach a final consensus after returning to 
the source of data. The analysis was done on a strict 
intention-to-treat b sis, attributing all target events to the 
treatment group to which the patients had been random- 
ized whether or not the patients were known to be 
compliant with the treatment. 
Statistical methods. The statistical analysis was done 
with the use of standard modifications of the Mantel- 
Haenszel stratified analysis of contingency tables. 26 These 
methods required, in each trial, the number of events 
observed in the dipyridamole group (O), the number of 
events that would be expected if there were no benefit 
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Table I I .  Details on the anticoagulant treatment used in the six controlled trials 
Anticoagulant drug Time started Timing of evaluations Basis for anticoagulant dosage 
Sullivan 19716 Warfarin 4 days after operation Every 6 months by hospital Control prothrombin time 
plus at intervals deter- values × 2 
mined by attending phy- 
sician 
Warfarin Every 2 weeks by hospital Kasahara 19777 1 or 2 days after opera- 
tion 
Boissel 1978 Phenindione or 7 days after operation 
(PACTE) 24 acenocoumarol 
Bran 1980 s Dicoumarin deriva- NA 
tives 
Rajah 19809 Warfarin 1 or 2 days after opera- 
tion 
Starkman 198225 NA 2 weeks after operation 
1 to 3weeks 
NA 
Every 6 weeks in the pro- 
thrombin clinic 
Every 3 to 4 weeks by at- 
tending physician 
Owren thrombotest 10% to 
25% of control values 
Quick time 25% to 35% of 
control value 
Quick time or Owren throm- 
botest (no target specified) 
Prothrombin ratio 1.9-3.0 
Quick time 25% to 35% of 
control 
NA, Information ot available. 
Table I I I .  Prevalence of events in the six controlled trials that used anticoagulants alone or in combination 
with dipyridamole 
ThromboemboIic Nonfatal Fatal thromboembolic 
events thromboembolic events events Deaths Hemorrhagic events 
Trial AVK + DIP AVK AVK + DIP AVK AVK + DIP AVK AVK + DIP AVK AVK + DIP AVK 
Sullivan 6 6/79 14/84 2/79 8/84 4/79 6/84 11/79 10/84 4/79 5/84 
Kasahara 7 2/39 8/39 2/39 2/39 0/39 6/39 3/39 7/39 1/39 1/39 
Boisse124 9/183 20/202 8/183 17/202 1/183 3/202 10/183 35/202 62/183 69/202 
Bran s 6/58 8/43 5/58 5/43 1/58 3/43 4/58 6/43 NA NA 
Rajah 9 3/68 11/87 2/68 8/87 1/68 3/87 7/68 6/87 4/68 7/87 
Starkman z5 5/132 8/127 5/132 8/127 0/132 0/127 5/132 3/127 9/132 5/127 
Total 31/559 69/582 24/559 48/582 7/559 21/582 40/559 67/582 80/501 87/539 
AV/~ Anticoagulants; DIP, dipyridamole; NA, information ot available. 
of dipyridamole (E), and the variance of this number of 
events (V). From O, E, and V one could calculate the 
odds ratio of the event in the dipyridamole group as 
compared with that in the control group, the confidence 
limits of this odds ratio, and a standardized deviate to test 
its statistical significance (test for treatment effect). The 
same calculations were done for the overall odds ratio by 
replacing O, E, and V by their summation over all trials) °
Individual odds ratios were represented graphically by a 
solid square, the surface of which is proportional to the 
corresponding variance V, that is, to the information 
content of that trial. Trials with many events have a large 
information ,content, and their odds ratio is therefore 
represented by a large square; conversely, trials with few 
events have a small information content, and their odds 
ratio is represented by a small square. For each end point, 
the relative benefit of dipyridamole was expressed as a risk 
reduction and its associated confidence interval (CI). An 
odds ratio equal to OR was taken as indicating a risk 
reduction of 1-OR. For each end point, a )(z statistic was 
also calculated to test any apparent differences between 
the results of the individual trials (test for heterogeneity). 
All CIs were calculated with use of a probability coverage 
of 95%. All p values were calculated with two-tailed tests. 
All calculations were done with the SAS software (SAS 
Institute, Cary, N.C.). 
Results 
Meta-analysis. Summary data extracted from 
each trial to per form the analyses are listed in Table 
I I I  and the results of the meta-analyses are dis- 
played in Figs. 1 to 5. 
The combinat ion of dipyridamole with anticoagu- 
lants reduced the risk of thromboembol ic  events 
(fatal or nonfatal) by 56% when compared with the 
risk with anticoagulants alone (95% CI of the risk 
reduction, 33% to 71%; Z = 3.85;p = 0.0001) (Fig. 1). 
The overall mortality rate was also significantly 
reduced by 40% in the group receiving dipyridamole 
(95% CI of the risk reduction, 10% to 60%; Z = 
2.47; p = 0.013) (Fig. 2). For this end point, 
however, the test for heterogeneity showed that 
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Study 
No. Events / No. Entered 
AVK+ DIP AVK O-  E Variance 
Relative Risk Risk Redn. 
(AVK + DIP:AVIO (SE) 
Boissel 
Sullivan 
Rajah 
Bran 
Kasahara 
Starkman 
9/183 
6/79 
3/68 
6/58 
20/202 - 4.8 6.7 
14/84 - 3.7 4.4 
11/87 - 3.1 3.2 
Total 
8/43 - 2 3 
2/39 8/39 - 3 2.2 
5/132 8/127 -1 .6  3.1 
31/559 69/582 -18 .3  
2 
Test for heterogeneity: X = 1.14 
5 
2P = 0.95 
22.6 
I 
0.0 
L . . . J  
t 
A 
I ! I E 
0.5 1.0 1.5 
AVK+DIP betterlAVK better 
AVK+DIP effect 2P=0.0001 
56% (14%) 
L 
2.0 
Fig. 1. Meta-analysis of all thromboembolic events, whether fatal or not, in six controlled trials that used 
warfarin or similar compounds (AVK) alone or in combination with dipyridamole (DIP). O, E, Frequency 
of observed and expected events; Risk Redn, risk reduction; SE, standard error of risk reduction. 
significant differences existed between individual 
trials (p = 0.046). Fig. 2 shows that most of the 
benefit in terms of overall mortality was a result of 
the findings of a single trial. 24 In this trial, patients 
were randomized before operation and all periop- 
erative deaths were included in the overall mortality 
in keeping with the intention-to-treat analysis. As it 
turns out, there was a major imbalance in periop- 
erative deaths between the two randomized groups 
in this trial (dipyridamole, 1;control group, 12), and 
this imbalance largely contributed to the observed 
difference between the dipyridamole and control 
groups. However, there was still a difference in favor 
of dipyridamole in this trial even after exclusion of 
the perioperative deaths (dipyridamole, 9; control 
group, 23). 
The benefit of dipyridamole on mortality was 
confirmed when fatal and nonfatal thromboembolic 
events were considered separately (Table III). In the 
dipyridamole group, there was, indeed, a 64% re- 
duction in the risk of death caused by thromboem- 
bolic events (95% CI of the risk reduction, 23% to 
83%; Z = 2.63; p = 0.008) without noticeable 
heterogeneity between trials (Fig. 3). When the two 
sudden deaths were excluded from this analysis 
(both of which had occurred in the control group), 
there was still a 61% risk reduction in favor of 
dipyridamole (p = 0.019). There was also a 50% 
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Study 
No. Events / No. Entered 
AVK+ DIP AVK O-  E Variance 
Relative Risk Risk Redn. 
(AVK+ DIP:AVK) (SE) 
Boissel 
Sullivan 
Rajah 
Bran 
Kasahara 
Starkman 
101183 35/202 -11.4 9.9 
11/79 10/84 0.8 4.6 
7/68 6•87 1.3 3 
4/58 6/43 - 1.7 2.2 
3/39 7/39 -2  2.2 
5/132 31127 0.9 1.9 
Total 401559 67/582 - 12.1 
2 
"first for heterogeneity: X = 11.26 2P = 0.046 
5 
I i 
r - - -  
23.9 ~ 40% (16%) 
t 
i 
I i I I [ I I 
0.0 0.5 1.0 1.5 
AVK + DIP better lAVK better 
AVK+ DIP effect 2P =0.013 
2, 
Fig. 2. Meta-analysis of total mortality (see legend of Fig. 1 for details). 
reduction in the risk of nonfatal thromboembolic 
events (95% CI of the risk reduction, 19% to 69%; 
Z = 2.80; p = 0.005) (Fig. 4). 
The occurrence of hemorrhagic events, whether 
fatal or not, did not differ between both treatment 
groups (Table III). The relative risk was almost 
identical in both treatment groups (95% CI of the 
risk reduction, -45% to 29%; Z -- 0.005;p = 0.94) 
(Fig. 5). There were too few fatal hemorrhages todo 
meaningful comparisons between the two groups 
(among the four trials with data on fatal hemor- 
rhages, four deaths were reported in the dipyridam- 
ole group versus five in the anticoagulants-alone 
group). 
Discuss ion  
Patients with prosthetic ardiac valves are perma- 
nently at hJigh risk of thromboembolic complica- 
tions. The pathologic events that lead to the throm- 
bus formation at the vane level are complex and 
involve both platelet aggregation and direct activa- 
tion of coagulation factors. I' 4, s Platelet activation 
may be sufficient o trigger the clotting system but 
there is also evidence that prosthetic materials can 
directly activate coagulation factor XII and induce 
thrombus formation independently of the platelets. 4 
Although anticoagulants such as warfarin act down- 
stream of factor XII in the coagulation cascade, the 
incidence of thromboembolic complications remains 
high in patients who receive anticoagulants alone, 
which led to clinical trials to explore the benefit of 
the combination of anticoagulants with antiplatelet 
drugs. 
The present meta-analysis clearly supports the 
recommendations on the use of dipyridamole in this 
indication I, 4, 5 and also casts some new light on the 
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Study 
No. Events / No. Entered 
AVK+ DIP AVK O-  E Variance 
Relative Risk Risk Redn. 
(AVK + DIP:AVK) (S E") 
Boissel 1/183 3/202 - 0.9 1 
Sullivan 4/79 6/84 - 0.8 2.4 
Rajah 1/68 3/87 - 0.8 1 
Bran 1/58 3/43 - 1.3 0.9 
Kasahara 0/39 6/39 - 3 1.4 
Total 7/427 21/455 - 6.8 
2 
Test for heterogeneity: X -- 2.97 
4 
2P = 0.56 
6.7 
I 
0.0 
I 
I 
i 
i 
,4-- 
i 
' I 
I 
i 
:r--- 
:L._ 
i 
L--: 
I 
i 
I 
t 
i 
i 
i 
i 
I 
I L i I 
0.5  1.0 1.5 
AVK+DIP better AVK better 
AVK+DIP effect 2P=0.008 
64% (24%) 
23 
Fig. 3. Meta-analysis of all fatal thromboembolic events, including sudden deaths (see legend of Fig. i for 
details). 
magnitude of the benefit and on the safety of the 
therapy. Obviously, meta-analyses have their limita- 
tions, but so have most statistical analyses done in 
published reports of individual clinical trials. In this 
respect, two features of the present meta-analysis 
deserve special emphasis. First, the data on which 
the calculations were based came from the registra- 
tion file submitted to the United States FDA, rather 
than solely from the published reports of the indi- 
vidual trials. Even though it would have been pref- 
erable to have information on the times to the target 
events for all individual patients, the analysis done 
on overall proportions of events yields a valid and 
powerful test of treatment benefit when, as is the 
case here, these events are relatively infrequent. 3°
Second, the data were analyzed with an intention- 
to-treat approach, so that all patients were kept in 
the group allocated by randomization regardless of 
outcome or treatment actually received. This had 
not always been done in the published papers, which 
may have seriously biased some of the reported 
results. The intention-to-treat approach is prefera- 
ble to an analysis of properly treated patients be- 
cause it is in general more conservative and is 
therefore less likely to conclude wrongly to a treat- 
ment benefit. In the present series of trials, the 
intention-to-treat approach may appear particularly 
problematic for the PACTE trial, 24 in which patients 
were randomized before operation and several days 
before the therapy was started. In this trial, because 
more patients died perioperatively in the control 
group than in the dipyridamole group, the intention- 
to-treat approach may have resulted in an overesti- 
mation of the benefit of dipyridamole on overall 
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No.Events/No.Entered 
Study AVK+DIP AVK O-E  Variance 
Relative Risk Risk Redn. 
(AVK + DIP:AVK) (SE) 
Boissel 8/183 17/202 -3 .9  5.6 
Sullivan 2/79 8/84 - 2.8 2.4 
Rajah 2/68 8187 - 2.4 2.3 
Bran 5/58 5/43 -0 .7  2.2 
Kasahara 2/39 2/39 0 1 
Starkman 5/132 8/127 -1.6 3.1 
Total 24/559 48/582 -11.5 
2 
Test for heterogeneity: X = 1.72 
5 
2P = 0.89 
I '  ! i 
LIL 
i 
1 
i 
[ - -A  L 
I 
i 
I 
i 
i 
i 
i 
i 
I 
I 
I 
i 
i 
i 
I L ,t_~ 
16.8 ~ 50% 08%) 
i 
[ L I i i I I 
0.0 0.5 1.0 1.5 2.1 
AVK+DIP betterlAVK better 
AVK+ DIP effect 2P =0.005 
Fig. 4. Meta-analysis ofnonfatal thromboembolic events (see legend of Fig. 1 for details). 
mortality. Nevertheless, this problem did not affect 
the analysis of fatal thromboembolic events, which 
did not include perioperative events, and the anal- 
ysis showed a major benefit of dipyridamole. It is 
noteworthy that in this meta-analysis there was also 
a clear risk reduction in favor of dipyridamole that 
remained significant regardless of the inclusion or 
elimination of the sudden deaths as thromboem- 
bolic events. 
Some concern could be expressed about the pos- 
sibility that thromboembolic events were defined 
and assessed ifferently in the trials considered. 
However, it should be stressed that the statistical 
techniques used in the present meta-analysis only 
compare patients receiving anticoagulants alone 
with those receiving combined therapy in the same 
trial. Hence the estimate of the benefit of dipyri- 
damole is valid within each trial. Differences in 
design between trials would only be important if the 
study designs were known to have a major influence 
on the benefit of adding dipyridamole to anticoagu- 
lants therapy. We have no evidence that this is 
indeed the case for the differences in design ob- 
served between the six trials, such as the end points 
used (Table I), the anticoagulant therapy (Table II), 
or the type and position of the prosthetic ardiac 
valve (data not shown). Even if there were underly- 
ing differences in the therapeutic benefit of dipyri- 
damole between various subgroups of patients, the 
number of trials and of observations would not 
permit their reliable detection. 31
The consistency ofthe results across all end points 
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No.Events/No.Entered 
Study AVK+DIP AVK O-E  Variance 
Relative Risk Risk Redn. 
(AVK + DIP:AVK) (SE') 
Boissel 62/183 69/202 -0.3 21.6 
Sullivan 4/79 5/84 -0.4 2.1 
Rajah 4/68 7/87 - 0.8 2.5 ~ - ~  
Kasahara 1/39 1/39 0 0.5 
Starkman 9/132 5/127 1.9 3.3 
Total 80/501 87/539 0.4 "~ I 30.1 
I i i i 
2 0,0 0.5 1,0 1.5 
Test for heterogeneity: X = 1.38 2P=0.85 AVK+DIP better AVK better 
4 
AVK+ DIP effect 2P=0.94 
I~ l~ 'W.  08*/.) 
I i 
La--.- 
2.( 
Fig. 5. Meta-analysis of all hemorrhagic events, whether fatal or not (see legend of Fig. 1 for details). 
examined, together with the positive results reported 
in other trials 1°-22 that did not meet our criteria for 
inclusion in the meta-analysis, strongly supports the 
efficacy of the combination therapy. With the use of 
dipyridamole there appeared to be a 56% risk reduc- 
tion in the prevalence of thromboembolic events, 
which is larger than the reductions reported with 
aspirin.iX, 32 Furthermore, the combination ofwarfarin 
with aspirin resulted in an increased prevalence of 
gastrointestinal tract and intracerebral bleeding, 1~ 
even in trials that used low doses of aspirin. 32 
Dipyridamole has a long safety record showing 
that if its use is sometimes limited by unpleasant 
side effects, it is devoid of serious adverse effects 
such as neutropenia, which may occur with other 
antiplatelet agents. 33' 34 It therefore appears to be a 
drug of choice to be combined with anticoagulants 
in patients with mechanical prostheses. One major 
safety concern, just as for aspirin, is the occurrence 
of hemorrhagic events, some of which may be fatal. 
Our meta-analysis showed no indication of a differ- 
ence in hemorrhagic events between the combined 
therapy and the use of anticoagulants alone, whether 
all events were considered or only fatal ones. If 
anything, the combined therapy showed fewer hem- 
orrhagic events, but the difference was far from 
statistical significance. The overall mortality differ- 
ence in favor of dipyridamole, together with the 
absence of any noticeable increase in bleeding com- 
plications, provides compelling evidence that the net 
effect of dipyridamole is beneficial. 
One may wonder whether the combined therapy 
is cost effective as compared with monotherapy with 
anticoagulants alone. Overall, the prevalence of 
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thromboembolic events was reduced from 11.86% 
with anticoagulant alone to 5.55% with the com- 
bined therapy. If 1000 patients were treated, this 
would result in 119 and 56 events, respectively. 
These events included cerebral emboli, peripheral 
emboli, valve', thrombi, and myocardial infarction. It 
was unclear :from the publications whether all non- 
fatal peripheral emboli and valve thrombi required 
hospitalizations. Nevertheless, patients with me- 
chanical prostheses and a suspected or obvious 
thromboembolic complication are usually hospital- 
ized, at least for a complete check-up. The duration 
of hospital stay for stroke or myocardial infarction 
ranges in our institution from 1 to more than 60 
days, with a mean of 17 _+ 5 days (standard error of 
the mean). On the basis of these figures, the addi- 
tional cost imposed by the administration of dipy- 
ridamole may well be more than compensated by 
the savings made by the prevention of hospitaliza- 
tion costs and the additional cost of outpatient 
treatment after a thromboembolic event. The long- 
term costs related to a permanent neurologic deficit 
(nursing, physiotherapy, and so on) further tip the 
financial balance in favor of dipyridamole therapy. 
Although a more detailed cost analysis would be 
warranted, as would a comparison between dipy- 
ridamole and low-dose aspirin therapy, it is likely 
that the drastic reduction in serious thromboem- 
bolic events, which require hospitalization and may 
lead to permanent disability, may make the treat- 
ment cost effective and clinically worthwhile. 
An unavoidable limitation of meta-analyses i  
that, by relying on past information, they may reach 
conclusions that are correct but no longer relevant 
at the time of their publication because of techno- 
logic or therapeutic progress. More than two de- 
cades have passed since the work of Sullivan, 
Harken, and Gorlin, 6 and during that period many 
technical improvements have been made to heart 
prostheses. Nevertheless, even in 1995, thromboem- 
bolic complications still probably remain the most 
common adverse vents in patients with mechanical 
valve prostheses. This entirely justifies not only 
revisiting dipyridamole efficacy but also considering 
alternative therapeutic approaches. Indeed, even 
combined therapy with dipyridamole is unable to 
completely prevent hromboembolic complications. 
Still, the positive results obtained with a combined 
therapy support he hypothesis that more powerful 
antiplate!et ',agents hat do not interfere with antico- 
agulant herapy could perhaps be even more effec- 
tive than dipyridamole. New powerful antiplatelet 
agents, such as thromboxane A2 antagonists, are 
now being explored in the clinical setting and the 
results of this meta-anatysis confirm that these com- 
pounds may be beneficial in patients with mechani- 
cal heart valves. 
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